Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Inovio Pharmaceuticals has dosed its first subject in phase 2 segment of its INNOVATE Phase 2/3 Clinical Trial for Covid-19 DNA vaccine candidate.
Inovio has dosed first patient in phase 2 segment of Covid-19 DNA vaccine candidate trial. (Credit: fernando zhiminaicela from Pixabay)
Subscribe to our email newsletter
The phase 2 segment has been designed to assess the safety and immunogenicity of INO-4800 Covid-19 vaccine candidate to confirm the dose for the subsequent efficacy assessment as part of the phase 3 segment of the trial.
INO-4800 is claimed to be the only nucleic-acid based vaccine, which is stable at room temperature for over a year and does not require to be frozen during transport or storage.
In November, Inovio secured approval from the US Food & Drug Administration (FDA) to begin phase 2 segment of its planned phase 2/3 clinical trial for its Covid-19 DNA vaccine candidate.
With a plan to complete enrolment by the end of this month, the phase 2 segment will recruit around 400 participants who are 18 years or older at up to 17 US sites.
INNOVATE is a randomised, blinded and placebo-controlled safety and efficacy study, which is funded by the US Department of Defense (DoD) Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) in coordination with the Office of the Assistant Secretary of Defense for Health Affairs (OASD (HA)) and the Defense Health Agency (DHA).
The phase 2 segment will assess safety, tolerability and immunogenicity of INO-4800 in a two-dose regimen, including 1.0mg or 2.0mg.
The patients will secure either INO-4800 or placebo in a three-to-one randomisation to confirm the more appropriate dosing level for each of three age groups, including 18-50 years, 51-64 years and 65 years and older, at high risk of SARS-CoV-2 exposure for the subsequent phase 3 efficacy assessment.
The DoD will offer funding for both the phase 2 and Phase 3 segments of INNOVATE, in addition to the $71m of funding earlier announced in June for the large-scale manufacture of the firm’s next-generation smart device Cellectra 3PSP and the procurement of Cellectra 2000 devices.
Inovio president and CEO Dr Joseph Kim said: “We’re pleased to move into the Phase 2 segment of our 2/3 trial on the pathway to establish our DNA technology as an integral component of the pandemic response given its potential for an outstanding safety profile and its demonstrable thermostability.”
